Chanca Piedra and Fatty Liver Disease: What the Trials Found
Chanca piedra has a long reputation as a liver herb. In fatty liver disease, the human evidence behind that reputation is three small randomized trials, and each one used a different plant material: a standardized Phyllanthus niruri extract, Phyllanthus urinaria, and a capsule that combined Phyllanthus niruri with milk thistle. Neither of the two trials that reported liver fat found a difference from placebo. None of the three found a difference between groups in liver enzymes. One found that a fibrosis score fell on the extract and not on placebo.
Most of the remaining evidence comes from rats, mice and cells. Those studies report less liver fat in animals fed a high-fat or deficient diet, and they are kept in their own section below, after the human results. The page ends with the safety findings, the drug-enzyme findings, the approved treatments and what is still not known.
Table of Contents
- Fatty Liver Disease Has a New Name
- Chanca Piedra Covers More Than One Species
- The Three Human Trials at a Glance
- The One-Year Phyllanthus niruri Trial
- The Phyllanthus urinaria Biopsy Trial
- The Phyllanthus niruri and Milk Thistle Combination Trial
- A Related Trial in Alcoholic Hepatitis
- Pooled Analyses Cover Hepatitis B, Not Fatty Liver
- Animal and Cell Studies on Liver Fat
- Safety Findings
- Drug-Enzyme Interaction Findings
- Approved Treatments and Their Trials
- What Is Not Known
- Key Research Papers
- Connections
- Featured Videos
Fatty Liver Disease Has a New Name
In 2023 a multisociety Delphi consensus, led by three large pan-national liver associations, chose metabolic dysfunction-associated steatotic liver disease (MASLD) as the name to replace nonalcoholic fatty liver disease (NAFLD). A total of 236 panelists from 56 countries took part. Seventy-four percent of respondents felt the old nomenclature was "sufficiently flawed to consider a name change", and the terms "nonalcoholic" and "fatty" were felt to be stigmatising by 61% and 66% of respondents. The new definition requires at least 1 of 5 cardiometabolic risk factors. People who meet it and also drink more alcohol per week (140-350 g/wk for females and 210-420 g/wk for males) fall into a separate category, metabolic and alcohol related/associated liver disease (PMID 37363821).
The same process replaced nonalcoholic steatohepatitis (NASH), the inflamed form of the disease, with metabolic dysfunction-associated steatohepatitis (MASH) (PMID 41231713). The chanca piedra trials below were written under the older names, so each is reported here in the words it used.
The condition is common. A 2023 systematic review of 92 studies (N=9,361,716) put its global prevalence over 1990–2019 at 30.05%, rising from 25.26% in 1990–2006 to 38.00% in 2016–2019 (PMID 36626630). A 2025 consensus report of the American Diabetes Association states that liver steatosis affects approximately two out of three people with type 2 diabetes and raises their risk of steatohepatitis, cirrhosis, liver cancer and liver-related death (PMID 40434108). The disease itself is covered in depth on the fatty liver disease page.
Chanca Piedra Covers More Than One Species
Chanca piedra is the common name for Phyllanthus niruri, a small annual herb found throughout the tropical and subtropical regions of both hemispheres. A 2017 review of the plant listed the taxonomic inconsistency of Phyllanthus niruri among the gaps in earlier studies (PMID 28512988). Close relatives, among them Phyllanthus amarus and Phyllanthus urinaria, are studied for the liver under overlapping names; a 2025 review of the genus covered many species traded in India as "Bhumyamalaki" (PMID 38642916), and a 1985 paper gives "Bhumyamlaki" as a Sanskrit name for Phyllanthus niruri itself (PMID 22557474).
The species matters for reading the research. A study of Phyllanthus amarus notes that many past studies and clinical trials of the plant gave contentious results, which its authors say accentuates the need to standardize extracts (PMID 25755316). The 2011 Cochrane review of the hepatitis B trials called for future trials to report the species used (PMID 21491412). This page names the species in every study, because a result for one species is not a result for another.
Phyllanthus emblica, the fruit known as Indian gooseberry or amla, belongs to the same genus (PMID 34480995). It is a different plant from chanca piedra, and its studies are left out of this page. The species comparison page sets the three main species side by side.
The Three Human Trials at a Glance
| Trial | Plant material and amount | People and length | Main result |
|---|---|---|---|
| Abu Hassan et al., 2023 | Standardized Phyllanthus niruri extract; the trial gave 3,000 mg daily | Adults with mild-to-moderate nonalcoholic fatty liver disease; 112 on the extract, 114 on placebo; 12 months | No difference in liver fat score or liver enzymes; fibrosis score fell on the extract (p = 0.001) |
| Wong et al., 2013 | Phyllanthus urinaria; the abstract does not state the amount | 60 patients with biopsy-proven nonalcoholic steatohepatitis; 40 on Phyllanthus, 20 on placebo; 24 weeks | Not superior to placebo on the biopsy activity score (P = 0.24) |
| Shaker et al., 2025 | Capsule of 200 mg Phyllanthus niruri extract plus 100 mg milk thistle extract; the trial gave one or two capsules | 146 patients with an apparent risk factor for nonalcoholic steatohepatitis; three arms; 36 weeks | Liver enzymes fell within the dose groups, with no difference between the three groups in percent change |
The One-Year Phyllanthus niruri Trial
This was a 12-month randomized, double-blind, placebo-controlled trial in adults with mild-to-moderate nonalcoholic fatty liver disease. To enter, people needed a controlled attenuation parameter (CAP) score above 250 dB/m and a fibrosis score below 10 kPa. The trial gave a standardized Phyllanthus niruri extract at 3,000 mg daily (n = 112) or a placebo (n = 114). The main outcomes were the changes in the controlled attenuation parameter score and in liver enzymes, and the analysis was by intention to treat (PMID 37313177).
- Controlled attenuation parameter score: no difference. It changed by -15.05 ± 36.76 dB/m on the extract and -14.74 ± 41.08 dB/m on placebo (p = 0.869).
- Liver enzymes: no difference. The abstract reports no significant difference between the groups in the changes of liver enzyme levels.
- Fibrosis score: lower on the extract. It changed by -0.64 ± 1.66 kPa on the extract and 0.10 ± 1.61 kPa on placebo (p = 0.001).
- Other metabolic measures: these were secondary outcomes, and the abstract does not give their results.
- Safety: no major adverse events were reported in either group.
The authors concluded that the extract did not significantly reduce the controlled attenuation parameter score or liver enzyme levels, that the fibrosis score improved, and that further research is needed to determine its clinical benefits at different dosages.
The Phyllanthus urinaria Biopsy Trial
This was a placebo-controlled, parallel-group, double-blind randomized trial in 60 patients with histology-proven nonalcoholic steatohepatitis, meaning the diagnosis was made from a liver biopsy. Forty received Phyllanthus urinaria and 20 received placebo for 24 weeks. The abstract does not state the amount given. The authors tested the herb because it ameliorates steatohepatitis in animal studies. The main outcome was the change in the biopsy-based nonalcoholic fatty liver disease activity score (PMID 23034128).
- Activity score: no difference. It changed by -0.8 ± 1.4 on Phyllanthus and -0.3 ± 1.3 on placebo (P = 0.24).
- Steatosis, lobular inflammation, ballooning and fibrosis: the change in each was similar between the two groups.
- Within the Phyllanthus group: hepatic steatosis fell (-0.2 ± 0.7; P = 0.039) and ballooning grades fell (-0.4 ± 0.5; P < 0.001), but the authors judged the change small and of limited clinical significance.
- Blood tests: no difference. The changes in alanine aminotransferase (ALT), aspartate aminotransferase (AST), fasting glucose and the lipid profile did not differ significantly between the groups.
The authors' conclusion: Phyllanthus is not superior to placebo in improving the activity score in patients with nonalcoholic steatohepatitis. This is the only trial of the three that judged the liver by biopsy.
The Phyllanthus niruri and Milk Thistle Combination Trial
This phase II, randomized, double-blind, placebo-controlled, three-arm trial tested a combined product of Phyllanthus niruri and milk thistle (Silybum marianum) extracts. Each capsule held 200 mg of a powdered extract from the aerial parts of Phyllanthus niruri and 100 mg of a powdered extract from milk thistle fruits. The trial gave placebo, one capsule (low dose) or two capsules (high dose) to 146 patients with an apparent risk factor for nonalcoholic steatohepatitis, randomized 1:1:1, for 36 weeks (PMID 39789561).
- Alanine aminotransferase fell within both dose groups: from 57 IU/L to 40 IU/L in the low-dose group (p = 0.026) and from 61 IU/L to 47.5 IU/L in the high-dose group (p < 0.0001).
- Aspartate aminotransferase fell within the high-dose group: from 43.5 IU/L to 32 IU/L (p = 0.001).
- Between the groups: no difference. The relative percent change did not differ significantly between the three groups for alanine aminotransferase (p = 0.465) or aspartate aminotransferase (p = 0.632).
- Fib-4 fibrosis score: no difference between the three groups at the end of treatment (p = 0.985).
- Lipids: no significant change in any group except total cholesterol in the low-dose group, which fell from 210 IU/L to 187 IU/L, p = 0.031 (units as the abstract prints them).
- Liver fat and stiffness: the controlled attenuation parameter and kPa scores were evaluated, but the abstract does not give their results.
- Safety: the capsules were safe and well tolerated over 36 weeks.
The authors wrote that the liver-protective effect in patients at risk of steatohepatitis still needs further assessment with more accurate investigation tools, a larger sample size and/or higher doses. The trial was registered retrospectively. Because every capsule also held milk thistle, its results cannot be credited to chanca piedra alone; the milk thistle page covers that herb.
A Related Trial in Alcoholic Hepatitis
One more randomized trial of Phyllanthus niruri concerns a different liver disease. In a block-randomized, double-blind, placebo-controlled trial in mild-to-moderate alcoholic hepatitis, 454 patients were screened, 100 were recruited and 71 were analyzed over 4 weeks. Liver and kidney function tests failed to show significant improvement with the plant. Total antioxidant levels rose (P = 0.034) and the authors reported an appetite-stimulant effect (P = 0.03) (PMID 34975132). It was not a fatty-liver trial, and its result cannot be read as one.
Pooled Analyses Cover Hepatitis B, Not Fatty Liver
No pooled analysis of Phyllanthus in fatty liver disease is among the records behind this page. The pooled analyses that exist are of chronic hepatitis B, a viral disease, and they are given here only as context for how the plant has fared in liver trials generally. The full account is on the hepatitis B page.
- 2001 systematic review: 22 randomized trials (n=1947); methodological quality was high in five double-blind trials and low in the other 17. Phyllanthus species had a positive effect on clearing hepatitis B surface antigen (HBsAg) from the blood compared with placebo or no intervention (relative risk 5.64, 95% CI 1.85-17.21). The authors judged the evidence not strong, citing low methodological quality and variations of the herb. No serious adverse event was reported (PMID 11555193).
- 2011 Cochrane review: 16 randomized trials with 1326 patients. The single trial against placebo (42 participants) found no significant difference in the outcome it measured. Phyllanthus added to an antiviral drug did better than the drug alone on some virus markers, but heterogeneity was substantial. None of the trials reported liver histology. The reviewers found no convincing evidence that phyllanthus compared with placebo benefits patients with chronic hepatitis B (PMID 21491412).
- 2013 Cochrane review against antiviral drugs: five randomized trials with 290 patients, all at high risk of bias, and no data on adverse events. The reviewers found insufficient evidence to support or refute phyllanthus for chronic hepatitis B (PMID 23633363).
- 2003 review of antiviral herbs: of 14 trials of Phyllanthus species for hepatitis B, seven reported positive and seven reported negative results (PMID 12741619).
A 2025 review of many Phyllanthus species concluded, from in vitro and in vivo studies, that they had considerable liver-protective potential (PMID 38642916). That conclusion rests on laboratory and animal work, which is the subject of the next section.
Animal and Cell Studies on Liver Fat
Every result in this section comes from animals or cells, not people.
- Phyllanthus niruri in high-fat-diet rats (2017): in male Sprague-Dawley rats with fatty liver induced by a special high-fat diet, a 50% methanolic extract, the strongest of three extracts tested, reduced liver enlargement (16%) and visceral fat weight (22%), decreased the fatty-liver score, prevented fibrosis, and lowered serum total cholesterol (48%), low-density lipoprotein (65%), alanine aminotransferase (45%), insulin (67%), the homeostatic model assessment of insulin resistance (73%) and liver triglyceride (29%) compared with untreated high-fat-diet rats. Ellagic acid and phyllanthin were identified as major compounds (PMID 28718838).
- The same extract, mechanisms (2018): in rats given eight weeks of high-fat diet and then four weeks of treatment, the extract raised serum adiponectin, lowered several inflammatory signals and showed antiangiogenic (blood-vessel-growth-blocking) activity in the aortic ring assay and in vitro tests (PMID 30096951).
- A nanoparticle form in obese rats (2026): Phyllanthus niruri extract loaded into niosomal nanocarriers reduced body weight, liver steatosis and inflammation in high-fat-diet rats; giving exendin 9–39 at the same time reversed these effects, which the authors took as confirming that they depend on the glucagon-like peptide-1 receptor. The authors wrote that the plant's usefulness is limited by poor bioavailability (PMID 42045980).
- Phyllanthus urinaria in cells and mice (2008): in cultured liver cells exposed to a methionine-and-choline-deficient medium, the herb reduced fat and enzyme release in a dose-dependent manner; in mice fed that deficient diet for 10 days, it prevented liver fat accumulation and steatohepatitis (PMID 18157836). This is the animal work that the 2013 human trial set out to test; in people, the herb was not superior to placebo.
- Alcohol and heated oil in rats (2010): a water extract of Phyllanthus niruri leaves lowered cholesterol, triglycerides and free fatty acids raised by alcohol plus heated sunflower oil, and prevented the release of liver enzymes (PMID 20843268).
- Alcohol-induced fatty liver in rats (1985): the powdered herb brought the extra triglyceride, cholesterol and phospholipid deposited in the liver, brain, kidney and heart back towards normal values (PMID 22557474).
- Phyllanthin, a lignan of Phyllanthus amarus (2015): in mice with liver fibrosis induced by carbon tetrachloride, phyllanthin reduced fibrosis by down-regulating the transforming growth factor beta signaling pathway (PMID 26337812).
- Geraniin, an ellagitannin: geraniin and amariin isolated from Phyllanthus amarus protected mouse liver slices against ethanol damage (PMID 22982332). In rats with metabolic syndrome from a high-fat diet, geraniin, described in that study as a polyphenol of rambutan rind, reduced fat deposits in the visceral fat and liver when the study gave 25 mg/kg for 4 weeks (PMID 32916379).
Safety Findings
In the human trials
- One-year Phyllanthus niruri trial: no major adverse events in either group (PMID 37313177).
- Combination trial: the capsules were safe and well tolerated over 36 weeks (PMID 39789561).
- The abstract of the Phyllanthus urinaria trial does not report on adverse events (PMID 23034128).
- Hepatitis B trials: the 2011 Cochrane review found only two trials that reported adverse events with numbers, without significant differences, and no serious adverse events (PMID 21491412).
- Kidney-stone research: a 2025 systematic review states that the evidence consistently supports the long-term safety of Phyllanthus niruri, confirmed by serial measurements of serum electrolytes and liver function (PMID 40480426).
In animals
- Pregnancy in rats: a water extract of Phyllanthus niruri given through pregnancy did not harm reproductive performance and was not teratogenic, but at 600 mg/kg it changed maternal kidney weight and structure, and it caused fetal macrosomia (oversized fetuses) and increased ossification sites. The authors concluded that the leaf extract can produce detrimental effects during pregnancy (PMID 32145330).
- Pregnancy and nursing in rats: at 75 and 150 mg/kg the extract changed the mothers' biochemical markers of liver function, and the male pups opened their ear canals and eyes early and showed anxiolytic-like behavior as adults. The authors concluded that the exposure did not induce changes sufficient to indicate maternal or postnatal toxicity. Their background notes that use of the plant is contraindicated during pregnancy and breastfeeding (PMID 39694168).
- Immune suppression in mice: phyllanthin from Phyllanthus amarus inhibited cellular and humoral immune responses in a dose-dependent way; at 100mg/kg its reduction of CD4+ and CD8+ cells was comparable to that of cyclosporin A at 50mg/kg (PMID 27765364).
Supplement liver injury in general
A 2017 research symposium review reported that herbal and dietary supplements account for 20% of cases of liver toxicity in the United States based on research data. It named anabolic steroids, green tea extract and multi-ingredient nutritional supplements as the major implicated agents, and noted that in multi-ingredient products the responsible component is usually unknown or can only be suspected (PMID 27677775). The review's abstract does not name Phyllanthus. The full safety picture is on the chanca piedra safety page.
Drug-Enzyme Interaction Findings
The plant's effect on the liver enzymes that clear drugs is part of its safety picture. The findings below are from human liver tissue, human cells and rats, not from interaction studies in people.
- Human liver microsomes (2011): extracts of Phyllanthus amarus inhibited cytochrome P450 3A4 (CYP3A4) and, weakly, CYP1A2, CYP2D6 and CYP2E1. Its lignans phyllanthin and hypophyllanthin were potent mechanism-based inhibitors of cytochrome P450 3A4. The authors wrote that taking the plant with drugs metabolized by this enzyme may potentially result in herb-drug interactions (PMID 21178301).
- Rats (2012): a single oral dose of Phyllanthus amarus extract (800 mg/kg) given 1 h before oral midazolam increased the drug's peak level and total exposure by 3.9- and 9.6-fold. Daily dosing for 15 days instead slightly induced liver CYP3A and CYP2B1/2, so the extract showed dual effects (PMID 22339466).
- Human cells (2025): Phyllanthus amarus extract and its lignans activated two human drug-sensing receptors, raised cytochrome P450 3A4 messenger RNA but inhibited the enzyme's activity, raised CYP1A2 activity in liver cells, and weakly inhibited drug transporters. The authors wrote that overconsumption may change how substrate drugs are handled and that further studies are warranted to strengthen the clinical relevance (PMID 39571700).
Approved Treatments and Their Trials
When the Phyllanthus urinaria trial was published in 2013, its authors wrote that there was no approved drug treatment for nonalcoholic steatohepatitis (PMID 23034128). That has since changed.
- Resmetirom: in a phase 3 trial of 966 adults with biopsy-confirmed nonalcoholic steatohepatitis and fibrosis, the trial gave once-daily resmetirom 80 mg or 100 mg or placebo. At week 52, steatohepatitis resolved with no worsening of fibrosis in 25.9% and 29.9% of the resmetirom groups versus 9.7% on placebo, and fibrosis improved by at least one stage in 24.2% and 25.9% versus 14.2%. Diarrhea and nausea were more frequent with resmetirom (PMID 38324483). A 2025 review states that resmetirom has been approved for noncirrhotic adults with metabolic dysfunction-associated steatotic liver disease and moderate to severe liver fibrosis, along with diet and exercise (PMID 41231713).
- Semaglutide: the November 2025 practice guidance update of the American Association for the Study of Liver Diseases reports accelerated approval by the U.S. Food and Drug Administration in August 2025 for steatohepatitis with moderate-to-advanced fibrosis. In the interim results of its phase 3 trial, which gave 2.4 mg/week by injection for 72 weeks, the drug resolved steatohepatitis without worsening of fibrosis in 62.9% versus 34.3% on placebo, and reduced fibrosis by at least one stage in 36.8% versus 22.4%. The guidance states that lifestyle modification remains the cornerstone of management alongside the drug (PMID 41201884).
Each of the three Phyllanthus trials compared the plant material with a placebo. None tested it against or alongside resmetirom or semaglutide. Decisions about medicines and supplements for the liver belong with a clinician.
What Is Not Known
- Whether any chanca piedra species lowers liver fat in people. The two trials that reported a liver fat measure found no difference from placebo.
- What the fibrosis-score fall in the one-year trial means for patients. Its authors wrote that further research is needed to determine the clinical benefits at different dosages (PMID 37313177).
- Which ingredient acted in the combination trial, and whether larger trials, more accurate tools or higher doses would show a difference between groups; its authors called for all three (PMID 39789561).
- Long-term outcomes. None of the three trials reports cirrhosis, liver cancer or deaths among its outcomes.
- The right species, preparation and dose. The trials used three different materials, and the hepatitis B reviewers called for species reporting and dose-finding designs (PMID 21491412). A 2025 review describes poor bioavailability as a limit on the therapeutic use of Phyllanthus amarus (PMID 40901185).
- Whether the enzyme findings cause drug interactions in people. The evidence is from liver tissue, cells and rats, and its authors called for further studies of the clinical relevance (PMID 39571700).
Key Research Papers
- Abu Hassan MR, Hj Md Said R, Zainuddin Z, Omar H, Md Ali SM, Aris SA, et al. Effects of one-year supplementation with Phyllanthus niruri on fibrosis score and metabolic markers in patients with non-alcoholic fatty liver disease: A randomized, double-blind, placebo-controlled trial. Heliyon. 2023;9(6):e16652. PubMed PMID: 37313177
- Wong VW, Wong GL, Chan AW, Chu WC, Choi PC, Chim AM, et al. Treatment of non-alcoholic steatohepatitis with Phyllanthus urinaria: a randomized trial. J Gastroenterol Hepatol. 2013;28(1):57-62. PubMed PMID: 23034128
- Shaker MK, Hassany M, Eysa B, Adel A, Zidan A, Mohamed S. The activity of a herbal medicinal product of Phyllanthus niruri and Silybum marianum powdered extracts (Heptex®) in patients with apparent risk factors for nonalcoholic steatohepatitis: a phase II, multicentered, randomized, double-blind, placebo-controlled clinical trial. BMC Complement Med Ther. 2025;25(1):8. PubMed PMID: 39789561
- Sowjanya K, Girish C, Bammigatti C, Prasanna Lakshmi NC. Efficacy of Phyllanthus niruri on improving liver functions in patients with alcoholic hepatitis: A double-blind randomized controlled trial. Indian J Pharmacol. 2021;53(6):448-456. PubMed PMID: 34975132
- Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78(6):1966-1986. PubMed PMID: 37363821
- Osta EG, Saenz F, Jaganathan S, Thomas C, Tsai E, Surabhi V, et al. Current Update on Nomenclature, Diagnosis, and Management of Metabolic Dysfunction-associated Steatotic Liver Disease: Radiologists' Perspective. Radiographics. 2025;45(12):e240221. PubMed PMID: 41231713
- Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023;77(4):1335-1347. PubMed PMID: 36626630
- Cusi K, Abdelmalek MF, Apovian CM, Balapattabi K, Bannuru RR, Barb D, et al. Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in People With Diabetes: The Need for Screening and Early Intervention. A Consensus Report of the American Diabetes Association. Diabetes Care. 2025;48(7):1057-1082. PubMed PMID: 40434108
- Kaur N, Kaur B, Sirhindi G. Phytochemistry and Pharmacology of Phyllanthus niruri L.: A Review. Phytother Res. 2017;31(7):980-1004. PubMed PMID: 28512988
- Pratima H, Shiraguppi A, Joojagar P, Shah K, Cheeraladinni SS, Singh PS, et al. Phytochemical profile and hepatoprotective potentiality of Phyllanthus genus: a review. J Pharm Pharmacol. 2025;77(2):189-205. PubMed PMID: 38642916
- Umarani D, Devaki T, Govindaraju P, Shanmugasundaram KR. Ethanol induced metabolic alterations and the effect of phyllanthus niruri in their reversal. Anc Sci Life. 1985;4(3):174-80. PubMed PMID: 22557474
- Krithika R, Verma RJ, Shrivastav PS, Suguna L. Phyllanthin of Standardized Phyllanthus amarus Extract Attenuates Liver Oxidative Stress in Mice and Exerts Cytoprotective Activity on Human Hepatoma Cell Line. J Clin Exp Hepatol. 2011;1(2):57-67. PubMed PMID: 25755316
- Saini R, Sharma N, Oladeji OS, Sourirajan A, Dev K, Zengin G, et al. Traditional uses, bioactive composition, pharmacology, and toxicology of Phyllanthus emblica fruits: A comprehensive review. J Ethnopharmacol. 2022;282:114570. PubMed PMID: 34480995
- Liu J, Lin H, McIntosh H. Genus Phyllanthus for chronic hepatitis B virus infection: a systematic review. J Viral Hepat. 2001;8(5):358-66. PubMed PMID: 11555193
- Xia Y, Luo H, Liu JP, Gluud C. Phyllanthus species for chronic hepatitis B virus infection. Cochrane Database Syst Rev. 2011;2011(4):CD008960. PubMed PMID: 21491412
- Xia Y, Luo H, Liu JP, Gluud C. Phyllanthus species versus antiviral drugs for chronic hepatitis B virus infection. Cochrane Database Syst Rev. 2013;2013(4):CD009004. PubMed PMID: 23633363
- Martin KW, Ernst E. Antiviral agents from plants and herbs: a systematic review. Antivir Ther. 2003;8(2):77-90. PubMed PMID: 12741619
- Al Zarzour RH, Ahmad M, Asmawi MZ, Kaur G, Saeed MAA, Al-Mansoub MA, et al. Phyllanthus Niruri Standardized Extract Alleviates the Progression of Non-Alcoholic Fatty Liver Disease and Decreases Atherosclerotic Risk in Sprague-Dawley Rats. Nutrients. 2017;9(7):766. PubMed PMID: 28718838
- Zarzour RHA, Alshawsh MA, Asif M, Al-Mansoub MA, Mohamed Z, Ahmad M, et al. Adipocytokine Regulation and Antiangiogenic Activity Underlie the Molecular Mechanisms of Therapeutic Effects of Phyllanthus niruri against Non-Alcoholic Fatty Liver Disease. Nutrients. 2018;10(8):1057. PubMed PMID: 30096951
- Khater SI, Hussein MMA, Abdel-Magied SS, Lotfy MM, Khamis T, Abdelaziz S, et al. Phyllanthus niruri niosomes ameliorate obesity-induced hepatic steatosis in rats via modulating MALAT1/miR-206/GLP-1R signaling and hepatic lipid metabolism. Biol Res. 2026;59(1):27. PubMed PMID: 42045980
- Shen B, Yu J, Wang S, Chu ES, Wong VW, Zhou X, et al. Phyllanthus urinaria ameliorates the severity of nutritional steatohepatitis both in vitro and in vivo. Hepatology. 2008;47(2):473-83. PubMed PMID: 18157836
- Latha P, Chaitanya D, Rukkumani R. Protective effect of Phyllanthus niruri on alcohol and heated sunflower oil induced hyperlipidemia in Wistar rats. Toxicol Mech Methods. 2010;20(8):498-503. PubMed PMID: 20843268
- Krithika R, Jyothilakshmi V, Prashantha K, Verma RJ. Mechanism of protective effect of phyllanthin against carbon tetrachloride-induced hepatotoxicity and experimental liver fibrosis in mice. Toxicol Mech Methods. 2015;25(9):708-17. PubMed PMID: 26337812
- Londhe JS, Devasagayam TP, Foo LY, Shastry P, Ghaskadbi SS. Geraniin and amariin, ellagitannins from Phyllanthus amarus, protect liver cells against ethanol induced cytotoxicity. Fitoterapia. 2012;83(8):1562-8. PubMed PMID: 22982332
- Cheng HS, Goh BH, Phang SCW, Amanullah MM, Ton SH, Palanisamy UD, et al. Pleiotropic ameliorative effects of ellagitannin geraniin against metabolic syndrome induced by high-fat diet in rats. Nutrition. 2020;79-80:110973. PubMed PMID: 32916379
- Iregui-Parra J, Rojas Ossa V, Arias Salazar CM, López Estupiñán AD, Díaz Varela D, Sinisterra Parra LM, et al. Phyllanthus niruri in the management of nephrolithiasis: A systematic review of the literature. Actas Urol Esp (Engl Ed). 2025;49(6):501791. PubMed PMID: 40480426
- Paula VG, Cruz LL, Sene LB, Gratão TB, Soares TS, Moraes-Souza RQ, et al. Maternal-fetal repercussions of Phyllanthus niruri L. treatment during rat pregnancy. J Ethnopharmacol. 2020;254:112728. PubMed PMID: 32145330
- Costa Alves MD, Pereira DE, Bidô RCA, de Andrade CMS, Rufino Freitas JC, Bertozzo CCMS, et al. Phyllanthus niruri L. Administration during pregnancy and breastfeeding: Maternal evaluation and effects on initial development and adult behavior of male rat offspring. Brain Res. 2025;1850:149402. PubMed PMID: 39694168
- Ilangkovan M, Jantan I, Bukhari SN. Phyllanthin from Phyllanthus amarus inhibits cellular and humoral immune responses in Balb/C mice. Phytomedicine. 2016;23(12):1441-1450. PubMed PMID: 27765364
- Navarro VJ, Khan I, Björnsson E, Seeff LB, Serrano J, Hoofnagle JH. Liver injury from herbal and dietary supplements. Hepatology. 2017;65(1):363-373. PubMed PMID: 27677775
- Taesotikul T, Dumrongsakulchai W, Wattanachai N, Navinpipat V, Somanabandhu A, Tassaneeyakul W, et al. Inhibitory effects of Phyllanthus amarus and its major lignans on human microsomal cytochrome P450 activities: evidence for CYP3A4 mechanism-based inhibition. Drug Metab Pharmacokinet. 2011;26(2):154-61. PubMed PMID: 21178301
- Taesotikul T, Nakajima M, Tassaneeyakul W, Yokoi T. Effects of Phyllanthus amarus on the pharmacokinetics of midazolam and cytochrome P450 activities in rats. Xenobiotica. 2012;42(7):641-8. PubMed PMID: 22339466
- Husain I, Abdulrahman B, Dale OR, Katragunta K, Idrisi M, Gurley BJ, et al. Interaction of Phyllanthus amarus extract and its lignans with human xenobiotic receptors, drug metabolizing enzymes and drug transporters. J Ethnopharmacol. 2025;339:119142. PubMed PMID: 39571700
- Harrison SA, Bedossa P, Guy CD, Schattenberg JM, Loomba R, Taub R, et al. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis. N Engl J Med. 2024;390(6):497-509. PubMed PMID: 38324483
- Bansal MB, Patton H, Morgan TR, Carr RM, Dranoff JA, Allen AM. Semaglutide therapy for metabolic dysfunction-associated steatohepatitis: November 2025 updates to AASLD Practice Guidance. Hepatology. 2026;83(5):1326-1340. PubMed PMID: 41201884
- Anyiam AF, Muhibi MA, Arinze-Anyiam OC, Obeagu EI. Enhancing the bioavailability of Phyllanthus amarus: implications for traditional and modern medicine in Africa. Ann Med Surg (Lond). 2025;87(9):5631-5636. PubMed PMID: 40901185
PubMed Topic Searches
Connections
- Chanca Piedra — Benefits Deep Dive — the hub for this article
- Chanca Piedra — the main topic page
- Chanca Piedra for Liver Protection — the wider liver evidence
- Chanca Piedra for Blood Sugar — the glucose research
- Chanca Piedra for Kidney Stones — the plant's best-known use
- Chanca Piedra for Uric Acid and Gout — uric acid and blood pressure
- Chanca Piedra for Hepatitis B — the pooled hepatitis B trials
- Phyllanthus Species Comparison — niruri, amarus and urinaria
- Chanca Piedra Safety and Drug Interactions — the full safety page
- Metabolic Dysfunction-Associated Steatotic Liver Disease — the disease itself
- Berberine and Fatty Liver — another herb's fatty-liver trials
- Milk Thistle — the second herb in the combination trial